Browsing by Title
Now showing items 2125-2144 of 3226
-
p.Val804Met, the most frequent pathogenic mutation in RET, confers a very low lifetime risk of medullary thyroid cancer.
(Endocrine Society, 2018-03-23)To date, penetrance figures for medullary thyroid cancer (MTC) for variants in RET have been estimated from families ascertained on account of presence of MTC. -
P032 SURGICAL SITE INFECTIONS FOLLOWING EMERGENCY HERNIA REPAIR: A SUB-STUDY FROM THE MASH PROJECT
Acutely symptomatic hernia (ASH) of the abdominal wall and groin are common presentations. Decisions related to repair technique can be driven by contamination and surgical site infection (SSI) risk. The aim of this study ... -
P046. Radiofrequency seeds compared with wire-guided localisation for occult breast lesions: Initial experience
(Elsevier, 2021-05-01)Introduction: Wire guided localisation (WGL) has been the mainstay for localisation for clinically occult breast lesions, though scheduling issues remain, particularly during covid-19. Hologic LOCalizer uses radiofrequency ... -
P100. High wavenumber Raman spectroscopy tissue differentiation for intraoperative margin analysis
(Elsevier, 2021-05-01)Introduction: Re-excision for positive margins occurs in almost 20% of patients undergoing Breast Conserving Surgery (BCS) with high institutional cost and patient psychological burden. High wavenumber Raman Spectroscopy ... -
P129 IBD care in the UK: A comprehensive, novel service assessment with feedback from 10,222 patients and 166 NHS organisations to inform a vision for quality improvement
(Oxford University Press, 2021-05-01)The IBD Benchmarking Tool, comprising an online Service Self-Assessment and Patient Survey, has provided a unique and comprehensive picture of Inflammatory Bowel Disease (IBD) care across the UK. The aim was to evaluate ... -
P135 Maintenance of antifibrotic treatment for IPF in the South West Peninsula & Exeter ILD service – a real world study
(BMJ, 2021-02-01)IPF is a life-limiting condition with an average prognosis of three years from diagnosis. The two anti-fibrotic therapies that are available, Pirfenidone and Nintedanib, can help slow progression of fibrosis and prolong ... -
P144 Red cell distribution width (RDW) and neutrophil lymphocyte ratio (NLR) as prognostic markers in idiopathic pulmonary fibrosis (IPF)
(BMJ, 2021-11-01)Introduction and Objectives Idiopathic Pulmonary Fibrosis (IPF) has a median survival of ~ 2–3 years, but there is significant variability and hence difficulty in advising patients at a personal level. The full blood count ... -
P158 Thoracic ultrasound on the respiratory post-take ward round: assessing the impact on clinical decision-making and the patient journey
(BMJ, 2021-11-01)Introduction Thoracic ultrasound (TUS) has become indispensable when assessing the acutely unwell respiratory patient. We examined the impact of TUS on clinical decision-making and patient management, inviting discussion ... -
P181 Patient-led remote intracapillary pharmacokinetic sampling (fingerPRICKS) for therapeutic drug monitoring in patients with Inflammatory Bowel Disease
(Oxford University Press, 2021-05-01)Because of COVID-19 public health restrictions, telemedicine has replaced conventional outpatient follow up for most patients with chronic immune-mediated inflammatory disorders treated with biologic drugs. Innovative ... -
P208 Correlation between physician and patient disease assessments in ulcerative colitis: 2-year UK data from the ICONIC study
(Oxford University Press, 2020-01-15)Background ICONIC is the largest prospective multi-country (n = 33) observational study assessing burden in adult ulcerative colitis (UC) patients under routine care. Both patient and physician assessments of disease ... -
P210 Not all Covid-19 deaths are hypoxic: observational cohort study of patients who died at the nightingale hospital Exeter
(BMJ, 2021-11-08)The Nightingale Hospital Exeter (NHE) with 116 beds designed to deliver respiratory support including non-invasive ventilation and high flow nasal oxygen, managed 242 patients with Covid-19 from November 2020 to February ... -
P246 Development of a new Inflammatory Bowel Disease Patient Identifier shortens time to clinic review and initiation of treatment
(Oxford University Press, 2021-05-01)Timely diagnosis of inflammatory bowel disease (IBD) is important because earlier use of biologic therapies leads to mucosal healing, a reduction in hospitalisations and surgeries and improvements in quality of life. In ... -
P361 PREPARE-IBD: Physician Responses to disease Flares and Patient Adaptation in Relation to Events in Inflammatory Bowel Disease during the COVID-19 pandemic: A multicentre cohort analysis
(Oxford University Press, 2022-01-21)The COVID-19 pandemic continues to pose complex problems across Europe and the world, with rising numbers of infections and the ongoing need for drastic public health interventions. This is difficult for patients with ... -
P387 Depression in biologic-treated patients with inflammatory bowel disease during the COVID19 pandemic
(Oxford University Press, 2021-05-01)Given the existential threat from COVID-19 and the consequent restrictive public health measures it is perhaps unsurprising that SARS-CoV-2 infection has been linked to increases in rates of depression in the general ... -
P413 Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for Crohn's disease
(Oxford Journals, 2017-02-01) -
P550 Clinical features of demyelination following anti-TNFα therapy.
(Oxford Journals, 2017-02) -
P648 The impact of infliximab therapeutic drug monitoring on decisions made in a virtual biologics clinic for IBD
(Oxford Journals, 2017-02-01) -
P92 Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multi-centre UK experience
(BMJ, 2021-01-01)Introduction Tofacitinib is an oral partially selective Janus kinase inhibitor approved for the treatment of refractory moderate to severe ulcerative colitis (UC). Real-world experience of patients with UC treated with ...